Evidence map›Paper›PMID 37139257›Full record

ArticlePatient preference and adherence2023

Patient Willingness to Use Digital Health Technologies: A Quantitative and Qualitative Survey in Patients with Cancer Cachexia.

Anil Tarachandani, Fikret Isik Karahanoglu, Andrew Messere, Lisa Tarasenko, Ann-Marie LaRonde-Richard, Nancy Kessler, Michelle Rossulek, Hans Plate, Kim Mahoney, Mar Santamaria

Open access · goldAbstract read
In one paragraph

Article in Patient preference and adherence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Anil TarachandaniEarly Clinical Development, Pfizer Inc., Cambridge, MA, USA.
Fikret Isik KarahanogluEarly Clinical Development, Pfizer Inc., Cambridge, MA, USA.ORCID 0000-0002-9162-8367
Andrew MessereEarly Clinical Development, Pfizer Inc., Cambridge, MA, USA.
Lisa TarasenkoGlobal Medical Affairs, Pfizer Inc., New York, NY, USA.
Ann-Marie LaRonde-RichardInternal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA.
Nancy KesslerBusiness Analytics and Insights, Pfizer Inc., New York, NY, USA.
Michelle RossulekInternal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA.
Hans PlatePensari LLC, Baltimore, MD, USA.
Kim MahoneyPensari LLC, Baltimore, MD, USA.
Mar SantamariaEarly Clinical Development, Pfizer Inc., Cambridge, MA, USA.
Pfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The objective of this study was to gain insights into the patients' perspectives on the impact of cancer cachexia on physical activity and their willingness to wear digital health technology (DHT) devices in clinical trials. Patients and Methods: We administered a quantitative 20-minute online survey on aspects of physical activity (on a 0-100 scale) to 50 patients with cancer cachexia recruited through Rare Patient Voice, LLC. A subset of 10 patients took part in qualitative 45-minute web-based interviews with a demonstration of DHT devices. Survey questions related to the impact of weight loss (a key characteristic in Fearon's cachexia definition) on physical activity, patients' expectations regarding desired improvements and their level of meaningful activities, as well as preferences for DHT. Results: Seventy-eight percent of patients reported that their physical activity was impacted by cachexia, and for 77% of them, such impact was consistent over time. Patients perceived most impact of weight loss on walking distance, time and speed, and on level of activity during the day. Sleep, activity level, walking quality and distance were identified as the most meaningful activities to improve. Patients would like to see a moderate improvement of activity levels and consider it meaningful to perform physical activity of moderate intensity (eg, walk at normal pace) on a regular basis. The wrist was the preferred location for wearing a DHT device, followed by arm, ankle, and waist. Conclusion: Most patients reported physical activity limitations since the occurrence of weight loss compatible with cancer-associated cachexia. Walking distance, sleep and quality of walk were the most meaningful activities to moderately improve, and patients consider moderate physical activity as meaningful. Finally, this study population found the proposed wear of DHT devices on the wrist and around the waist acceptable for the duration of clinical studies.

Indexed as

DHT devicemeaningful activitiespatients’ expectationsphysical activitywalking

Identifiers

PMID37139257
PMCPMC10150793
OpenAlexW4367322846

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.